Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0UPQJ)

Drug Name

Dotinurad Drug Info

Synonyms

Dotinurad; 1285572-51-1; FYU-981; Dotinurad [INN]; (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxidobenzo[d]thiazol-3(2H)-yl)methanone; 305EB53128; (3,5-dichloro-4-hydroxyphenyl)-(1,1-dioxo-2H-1,3-benzothiazol-3-yl)methanone; Urece; Methanone, (3,5-dichloro-4-hydroxyphenyl)(1,1-dioxido-3(2H)-benzothiazolyl)-; Urece (TN); Dotinurad (JAN/INN); DOTINURAD [JAN]; DOTINURAD [WHO-DD]; FYU981; CHEMBL4594446; SCHEMBL10322525; GTPL11389; VOFLAIHEELWYGO-UHFFFAOYSA-N; UNII-305EB53128; EX-A5737; BDBM50561689; AKOS040741664; HY-109031; CS-0030545; D11071; 3-(3,5-dichloro-4-hydroxybenzoyl)-1,1-dioxo-2,3-dihydro-1,3-benzothiazole

Indication

Disease Entry	ICD 11	Status	REF
Gout	FA25	Phase 3	[1]

Cross-matching ID

PubChem CID: 51349053
TTD Drug ID: DM0UPQJ

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Urate anion exchanger 1 (URAT1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lesinurad	DMUR64T	Hyperuricaemia	5C55.Y	Approved	[3]
URC102	DMY89BN	Gout	FA25	Phase 2	[4]
RDEA-684	DMNWYHD	Gout	FA25	Phase 2	[3]
RDEA3170	DM1TKG4	Hyperuricaemia	5C55.Y	Phase 2	[5]
AR882	DMFGYZ8	Gout	FA25	Phase 2	[6]
Sulfonamide derivative 11	DMJBR86	N. A.	N. A.	Patented	[7]
Cycloalkyl acid derivative 1	DMXMGSP	N. A.	N. A.	Patented	[7]
2-ethyl-3-(4-hydroxy) benzoyl benzofuran derivative 1	DMHYIAV	N. A.	N. A.	Patented	[7]
Tihoacetate derivative 1	DM6QHO0	N. A.	N. A.	Patented	[7]
Cycloalkyl acid derivative 2	DM09LY3	N. A.	N. A.	Patented	[7]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Urate anion exchanger 1 (URAT1)	TTA592U	S22AC_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT05007392) A Randomized, Multicenter, Double-Blind, Superiority Study of Dotinurad (4 mg) and Febuxostat (40 mg) for the Treatment of Subjects With Gout. U.S.National Institutes of Health.
2	Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout. Expert Opin Pharmacother. 2021 Aug;22(11):1397-1406.
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1031).
4	Clinical pipeline report, company report or official report of Chugai Pharmaceutical (2013).
5	The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol. 2013; 14: 164.
6	Clinical pipeline report, company report or official report of Arthrosi Therapeutics
7	Urate transporter URAT1 inhibitors: a patent review (2012 - 2015).Expert Opin Ther Pat. 2016 Jul 30:1-10.